<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052177</url>
  </required_header>
  <id_info>
    <org_study_id>University of Bordeaux</org_study_id>
    <nct_id>NCT05052177</nct_id>
  </id_info>
  <brief_title>Percutaneous Edge To Edge Repair for the Treatment of Severe Tricuspid Valve Regurgitation in High-surgical Risk Patients With Systemic Right Ventricle : a Multicentric French Cohort (PETER-TRESRIV)</brief_title>
  <acronym>PETER-TRESRIV</acronym>
  <official_title>Percutaneous Edge To Edge Repair for the Treatment of Severe Tricuspid Valve Regurgitation in High-surgical Risk Patients With Systemic Right Ventricle : a Multicentric French Cohort.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study is about to follow adult congenital patients, known with systemic right ventricle&#xD;
      (mostly correct transposition of the great arteries ou congenitally corrected transposition&#xD;
      fo the great arteries) and systemic valve severe regurgitation which was treated with a&#xD;
      Mitraclip device on this tricuspid valve.&#xD;
&#xD;
      It's an observationnal study with a 2 years follow up with clinical (symptoms, complications,&#xD;
      VO2 exercice test) echographic and MRI outcomes&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with systemic right ventricle (mostly congenitally-corrected transposition of the&#xD;
      great arteries or transposition of the great arteries corrected by atrial switch) commonly&#xD;
      develop significant systemic tricuspid valve regurgitation which is a therapeutic dilemma for&#xD;
      the care team. Surgery (valvuloplasty or replacement) is the common and historical treatment&#xD;
      but the rate of mortality is high and results about long-term benefit are contradicting.&#xD;
      Percutaneous edge to edge repair could be a alternative to surgery.&#xD;
&#xD;
      10 high-risk surgical patients with severe systemic tricuspid regurgitation undergoing a&#xD;
      percutaneous repair were included between January 2019 and November 2022. Our study is a&#xD;
      retrospective analysis of short and mid-term clinical, biological, echocardiographic and&#xD;
      MRI/TDM outcomes with an expected minimum follow-up of 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical, VO2 max testing, biological, echocardiographic, cross-sectionnal Imaging data.</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical data : dyspnea (NYHA 1/2/3/4), heart palpitations (yes/no), heart failure in the 6 previous months (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 max testing data.</measure>
    <time_frame>2 years</time_frame>
    <description>VO2 max testing: VO2 max (ml/min/kg), strenght in watts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological data.</measure>
    <time_frame>2 years</time_frame>
    <description>Biological data : hemoglobine (g/dL), hematocrit (%), creatinine (µmol/L), BNP/nt-proBNP (ng/mL) at baseline, 6, 12, 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echographic data.</measure>
    <time_frame>2 years</time_frame>
    <description>Echocardiographic data : tricuspid insuffisency severity (régurgitant orifice area in mm²), régurgitant volume (mL)), tricuspid annular diameter (cm), and right ventricle systemic function (S'VD in cm/s, TAPSE in mm, shortening right ventricle fraction in %), and area (end-diastolic and end-systolic area) at baseline, 6, 12, 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-sectionnal Imaging data.</measure>
    <time_frame>2 years</time_frame>
    <description>Cross-sectionnal imaging data : quantitative parameters of tricuspid regurgitation (regurgitant volume in mL, percentage of regurgitation in %) and right ventricle systemic function (ejection fraction in %) and volume (end-diastolic and end-systolic volume in mL) at baseline and 6 months.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Systemic Right Ventricle</condition>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk</arm_group_label>
    <description>inclusion criteria:&#xD;
&gt; 18-years-old&#xD;
Right systemic ventricle&#xD;
Severe tricuspid regurgitation&#xD;
Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy&#xD;
High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation&#xD;
exclusion criteria - pregnant ou breastfeeding women</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edge to edge repair in systemic tricuspid valve regurgitation</intervention_name>
    <description>Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.</description>
    <arm_group_label>Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic right ventricle who underwent a percutaneous edge to edge systemic&#xD;
        valve repair for the treatment of severe tricuspid valve regurgitation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18-years-old&#xD;
&#xD;
          -  Right systemic ventricle&#xD;
&#xD;
          -  Severe tricuspid regurgitation&#xD;
&#xD;
          -  Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy&#xD;
&#xD;
          -  High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and&#xD;
             thus having underwent a percutaneous treatment of tricuspid regurgitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre SILINI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre SILINI</last_name>
    <phone>0678746867</phone>
    <email>alexandre.silini@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier IRIART, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALEXANDRE SILINI</last_name>
      <phone>0678746867</phone>
      <email>alexandre.silini@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27777298/</url>
    <description>Filippov AA, del Nido PJ, Vasilyev NV. Management of Systemic Right Ventricular Failure in Patients With Congenitally Corrected Transposition of the Great Arteries. Circulation. 25 oct 2016;134(17):1293-302.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bordeaux</investigator_affiliation>
    <investigator_full_name>Alexandre Silini</investigator_full_name>
    <investigator_title>Intern</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

